

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Monocyte chemoattractant protein-1 (MCP-1; CCL2)	<i>In vitro</i> and mouse studies suggest inhibiting the nitrosylation of CCL2 could help increase the efficacy of adoptive cell transfer therapy in cancer. In three mouse models of cancer, a small molecule that blocked nitrosylation of CCL2 promoted tumor infiltration by T cells compared with vehicle control. In two mouse models of cancer, the small molecule plus transfer of tumor-specific T cells increased survival compared with tumor-specific T cell transfer alone. Next steps include testing the small molecule in additional mouse models of cancer.	Patent application filed; licensing status undisclosed	Molon, B. <i>et al. J. Exp. Med.</i> ; published online Sept. 19, 2011; doi:10.1084/jem.20101956 <b>Contact:</b> Barbara Molon, Scientific Institute for Hospitalization and Health Care, Venetian Oncological Institute, Padua, Italy e-mail: <a href="mailto:barbara.molon@unipd.it">barbara.molon@unipd.it</a>
		<b>SciBX 4(40); doi:10.1038/scibx.2011.1110</b> <b>Published online Oct. 13, 2011</b>		